Erectile dysfunction is a persistent or recurrent difficulty maintaining or achieving an erection sufficient for satisfactory sexual activity. It is one of the most commonly reported sexual dysfunctions in men and can have a dramatic impact on the quality of life of the individual and his partner's. Erectile dysfunction has a high prevalence and is an important marker of cardiovascular risk. There are many treatment options available and treating this symptom improves quality of life, well-being and can reduce the risk of subsequently developing cardiovascular disease.
Get full access to this article
View all access options for this article.
References
1.
Bernal, R. & Henry, G. (2012). Contemporary patient satisfaction rates for three piece inflatable penile prostheses. Advances in Urology, 2012, 1–5. doi: 10.1155/2012/707321.
2.
British Society for Sexual Health. Guidelines on erectile dysfunction. Retrieved from www.bssm.org.uk/downloads/.
3.
BuvatJ.MontorsiF.MaggiM.PorstH.KaipiaA.ColsonM. H.ShabsighR. (2011) Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). The Journal of Sexual Medicine8(1): 284–293. doi: 10.1111/j.1743-6109.2010.01956.x.
4.
InmanB.St SauverJ.JacobsonD.McGreeM.NehraA.LieberM.JacobsenS. (2009) A population-based longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clinic Proceedings84(2): 108–113. doi: 10.4065/84.2.108.
5.
KałkaD.DomagałaZ.DworakJ.WomperskiK.RusieckiL.MarciniakW.PileckiW. (2013) Association between physical exercise and quality of erection in men with ischaemic heart disease and erectile dysfunction subjected to physical training. Polish Heart Journal71(6): 573–580. doi: 10.5603/KP.2013.0120.
6.
KapoorD.GoodwinE.ChannerK. S.JonesT. H. (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology154: 899–906. Retrieved from http://eje-online.org/content/154/6/899.full.pdf+html.
7.
LevineG.SteinkeE.BakeenF.BozkurtB.CheitlinM. D.ContiJ. B.StewartW. J. (2012) Sexual activity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation125: 1058–1072. doi: 10.1161/CIR.0b013e3182447787.
8.
MontorsiP.MontorsiF.SchulmanC. C. (2003) Is erectile dysfunction the ‘tip of the iceberg’ of a systemic vascular disorder?European Urology44: 352–354. doi:10.1016/S0302-2838(03)00307-5.
PorstH.GiulianoF.GlinaS.GlinaS.RalphD.CasabéA. R.WhitakerS. (2006) Evaluation of the efficacy and safety of once a day dosing of taldalafil 5 mg and 10 mg in the treatment of erectile dysfunction: Results of a multicenter, randomised, double-blind, placebo-controlled trial. European Urology50: 351–359.
12.
PorstH.RoehrbornC. G.SecrestR. J.EslerA.ViktrupL. (2013) Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: Analyses of pooled data from four randomized, placebo-controlled clinical studies. Journal of Sexual Medicine10(8): 2044–2052. doi: 10.1111/jsm.12212.
ReynardJ.BrewsterS.BiersS. (2006) Oxford handbook of urology, Oxford, UK: Oxford University Press.
15.
RoseileR. C.FriedmanM.KostisJ. B. (2005) Lifestyle management of erectile dysfunction: The role of cardiovascular and concomitant risk factors. The American Journal of Cardiology96(12): 76–79. doi:10.1016/j.amjcard.2005.10.011.
16.
ScrantonR. E.GoldsteinI.StecherV. J. (2013) Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. Journal of Sexual Medicine10(2): 551–561. doi: 10.11111/j1743-6019.2012.02998.x.
Urciuoli, R., Cantisani, T. A., Carlini, M., Giuglietti, M., & Botti, F. (2004). Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database of Systematic Reviews, 2, article no.: CD001784. doi: 10.1002/14651858.CD001784.pub2.
Vardi, M. & Nini, A. (2007). Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database of Systematic Reviews, 1, article no.: CD002187. doi: 10.1002/14651858.CD002187.pub3.
